John Desjarlais on autoimmune disease
From Antibodies! Ep. 2: Fc Engineering & Bispecifics with John Desjarlais · · The Antibody Society
“The most disruptive paper that came out in the last couple of years in our field was the Georg Schett paper talking about use of CD19 CAR-T for treatment of autoimmune disease. Right, basically showing leading to a lot of hyperbolic headlines, but basically the concept that treatment with the CD19 targeted CAR-T could effectively put a number of lupus and Sjogren's and myositis patients into remission for long periods of time. Kind of a re-immune reset hypothesis.”
On , John Desjarlais, Executive Vice President of Research & Chief Scientific Officer at XENCOR INC, spoke about autoimmune disease during Antibodies! Ep. 2: Fc Engineering & Bispecifics with John Desjarlais on The Antibody Society.
About John Desjarlais
John Desjarlais, Executive Vice President of Research and Chief Scientific Officer at Xencor, appeared on the Antibodies! podcast recorded at the Antibody Engineering & Therapeutics conference in San Diego. During the conversation, Desjarlais discussed the application of T-cell engager bispecific antibodies in autoimmune disease, citing a paper by Georg Schett on CD19 CAR-T therapy for autoimmune conditions. He described a "gold rush" in deploying T-cell engager bispecific antibodies targeting B-cell antigens such as CD20, CD19, and BCMA, based on the hypothesis that B cells contribute to the pathogenesis of autoimmune diseases. Desjarlais noted that the field is working to determine the optimal depth and durability of B-cell depletion to achieve an "immune reset" while allowing the immune system to recover. Desjarlais also addressed challenges in using T-cell engagers for solid tumors, stating that the biggest challenge is not the immunoenvironment or T-cell presence, but rather the identification of highly selective targets that are overexpressed on tumor cells. He suggested that tri-specific antibodies targeting two tumor antigens could improve selectivity by requiring T cells to kill only when both targets are present, though he acknowledged technical challenges in developing such molecules with good developability and half-life.